Foamix to Present Corporate Overview at the 3rd Annual Dermatology Summit Meeting
04. Januar 2016 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Announces Positive Top-Line Results From Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers
03. Dezember 2015 07:00 ET
|
Foamix, Ltd.
FDX104 prevented the development of moderate-to-severe antibody-induced rash in the majority of cases.
FDX104 appears safe and was well-tolerated.
REHOVOT, Israel and BRIDGEWATER, N.J.,...
Foamix to Host Conference Call & Webcast to Discuss Topline Results From Phase 2 Study of FDX-104 in Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers
02. Dezember 2015 16:01 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing...
Foamix to Present Corporate Overview at the Oppenheimer 26th Annual Healthcare Conference
01. Dezember 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused...
Foamix to Present Corporate Overview at Jefferies Autumn 2015 Global Healthcare Conference in London
11. November 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...
Foamix Reports Third Quarter 2015 Financial Results and Provides Business Update
11. November 2015 07:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, November 11
27. Oktober 2015 13:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...
Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea
20. Oktober 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...
Foamix Reports Second Quarter 2015 Financial Results and Provides Business Update
19. August 2015 16:01 ET
|
Foamix, Ltd.
REHOVOT, Israel, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Pharmaceuticals Second Quarter 2015 Conference Call & Webcast Scheduled for Thursday, August 20
13. August 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...